Literature DB >> 21730270

Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.

Yasushi Yatabe1, Keitaro Matsuo, Tetsuya Mitsudomi.   

Abstract

PURPOSE: Some studies have shown that epidermal growth factor receptor (EGFR) mutations can be heterogeneously distributed in individual tumors. In this study, we re-evaluated the distribution of EGFR mutations within tumors. PATIENTS AND METHODS: We used multiple approaches, including an analysis of simultaneous dual hot spot mutations, a trans-sectional analysis of individual lung adenocarcinomas, and comparisons of the mutation patterns between primary and metastatic sites and between primary and recurrent tumors.
RESULTS: None of the 862 tumors harboring an EGFR mutation showed simultaneous dual hot spot mutations, although identical EGFR mutations were found throughout individual tumors in a trans-sectional analysis involving 50 tumors divided into three parts and five lung adenocarcinomas divided into 100 parts. In addition, no discordant mutation patterns were detected among 77 paired primary and metastatic site samples or among 54 primary and recurrent tumor pairs.
CONCLUSION: All of these results suggest that the heterogeneous distribution of EGFR mutations is extremely rare. However, it is possible that pseudoheterogeneity occurs because of a combination of mutant allele-specific imbalance and heterogeneously distributed EGFR amplification, especially when a less sensitive method is used for detection. Specifically, when EGFR amplification occurs, the mutant allele is amplified, and this amplification is involved in invasive growth. Accordingly, invasive growth area significantly over-represents the mutation signal. In contrast, weak EGFR mutation signals in the area without EGFR amplification may not reach the threshold of detection because of the mixture with normal cells. Such unbalanced mutation signals might lead to pseudoheterogeneity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21730270     DOI: 10.1200/JCO.2010.33.3906

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  89 in total

1.  ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens.

Authors:  Jinguo Liu; Ruiying Zhao; Jie Zhang; Jian Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-26       Impact factor: 4.553

2.  Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens.

Authors:  Li-Hui Tseng; Federico De Marchi; Aparna Pallavajjalla; Erika Rodriguez; Rena Xian; Deborah Belchis; Christopher D Gocke; James R Eshleman; Peter Illei; Ming-Tseh Lin
Journal:  Am J Clin Pathol       Date:  2019-10-07       Impact factor: 2.493

Review 3.  The quest to overcome resistance to EGFR-targeted therapies in cancer.

Authors:  Curtis R Chong; Pasi A Jänne
Journal:  Nat Med       Date:  2013-11-07       Impact factor: 53.440

4.  Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.

Authors:  Giuseppe Pelosi; Alessio Pellegrinelli; Alessandra Fabbri; Elena Tamborini; Federica Perrone; Giulio Settanni; Adele Busico; Benedetta Picciani; Maria Adele Testi; Lucia Militti; Patrick Maisonneuve; Barbara Valeri; Angelica Sonzogni; Claudia Proto; Marina Garassino; Filippo De Braud; Ugo Pastorino
Journal:  Virchows Arch       Date:  2016-04-07       Impact factor: 4.064

5.  The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer.

Authors:  Jingya Zhao; Xiaoying Wang; Liang Xue; Nuo Xu; Xin Ye; Haiying Zeng; Shaohua Lu; Jie Huang; Sujie Akesu; Chen Xu; Deming He; Yunshan Tan; Qunying Hong; Qun Wang; Guanshan Zhu; Yingyong Hou; Xin Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-22       Impact factor: 4.553

Review 6.  Management pathways for solitary pulmonary nodules.

Authors:  Masaoki Ito; Yoshihiro Miyata; Morihito Okada
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 7.  Surgery for NSCLC in the era of personalized medicine.

Authors:  Tetsuya Mitsudomi; Kenichi Suda; Yasushi Yatabe
Journal:  Nat Rev Clin Oncol       Date:  2013-02-26       Impact factor: 66.675

8.  Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases.

Authors:  Yalei Zhang; Haihong Yang; Xinyun Yang; Qiuhua Deng; Meilin Zhao; Xin Xu; Jianxing He
Journal:  Mol Clin Oncol       Date:  2014-02-11

Review 9.  Histopathologic and molecular approach to staging of multiple lung nodules.

Authors:  Frank Schneider; Sanja Dacic
Journal:  Transl Lung Cancer Res       Date:  2017-10

10.  EGFR mutation testing practice in advanced non-small cell lung cancer.

Authors:  Jair Bar; Arnold Cyjon; Dov Flex; Hadas Sorotsky; Haim Biran; Julia Dudnik; Nili Peylan-Ramu; Nir Peled; Hovav Nechushtan; Maya Gips; Rivka Katsnelson; Shoshana Keren Rosenberg; Ofer Merimsky; Amir Onn; Maya Gottfried
Journal:  Lung       Date:  2014-06-26       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.